TSE:4503Pharmaceuticals
How Investors Are Weighing Astellas Pharma Amid 2025 Price Fluctuations and Pipeline Hopes
If you have been eyeing Astellas Pharma’s stock lately, you are definitely not alone. Investors are weighing their options after a handful of ups and downs this year. Despite a modest slip of -1.2% over the past week and a slightly deeper -3.2% drop for the month, Astellas Pharma still finds itself up 6.4% year-to-date, hinting at a resilience that has caught the market’s attention. Over the longer term, the story is a bit more mixed, with a -1.3% return over one year and -6.6% across three...